About OmniBuds
OmniBuds, Inc. is developing an earbud that senses cardiovascular signals from the ear. It combines PPG, acoustic, motion and temperature readings. The aim is continuous blood pressure monitoring. The earbud is designed for everyday users, patients working with clinicians, and researchers. OmniBuds offers two solutions, OmniBuds Research and OmniBuds Clinical. The system is not cleared by the U.S. Food and Drug Administration and is not for sale in any market.
OmniBuds has its corporate headquarters in Nashville, Tennessee, and its research and development headquarters in Cambridge, United Kingdom. Ben Carter is chief executive officer. Jim Stefansic is chief operating officer and directs the U.S. business, including operations, finance, and regulatory and clinical work. Two other founders serve as chief technology officer and chief scientific officer.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 11, 2026 | Oct 21, 2026 | $2,999,991of $14.6M target | 2 | $1.4M | Equity, OptionsRule 506(b) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed OmniBuds
OmniBuds, Inc. is developing an earbud that reads cardiovascular signals from the ear. The product is still in development and has no FDA clearance. Its chief executive officer and chief operating officer have each co-founded earlier companies. According to Venture Nashville, the company is seeking about $14.6 million.
The problem it targets
OmniBuds' case is that deeper insight into the body should not depend on bulky devices or clinic visits. It argues that an ordinary earbud could reveal more about how the body responds to daily life. The technical roadmap points to hypertension management as well as continuous cardiovascular monitoring.
What the product does
The earbud captures PPG, acoustic, motion and temperature signals. Premium audio, multi-sensor biosensing and on-device AI sit in the same device. The site groups readings into five views: blood pressure, circadian profile, heart rhythm, stress levels and vascular profile. The wording is cautious. The blood pressure view explores signal patterns, and the circadian view captures patterns that may relate to blood pressure. Data is encrypted end to end, and users control what is shared.
Progress so far
The OmniBuds research platform was unveiled when the company was formed to advance earables for cardiovascular research. The original platform came from a team at Nokia Bell Labs led by the chief scientific officer. The site quotes people taking part in a study of the earbuds. The system has no FDA clearance. The stated goal is to meet medical device regulatory and quality standards before any launch.
Who backs it
According to Venture Nashville, OmniBuds is seeking roughly $14.6 million and has recruited just under $3 million so far. Chief executive officer Ben Carter co-founded B-Secur, which secured several FDA clearances and raised funding through Series B. Chief operating officer Jim Stefansic co-founded Pathfinder Therapeutics and raised more than $17 million in venture capital and SBIR funding there.
We wrote this summary from public statements by OmniBuds and its investors. It is not investment advice.
OmniBuds in the News
Leadership Team
Executive officers and directors listed on OmniBuds's Form D filed Oct 21, 2026.
Sources
- SECOmniBuds, Inc. filing history
- CompanyAbout OmniBuds
- CompanyContact OmniBuds